Type 1 diabetes immunotherapy using polyclonal regulatory T cells-Reference-Cited by-同舟云学术

Type 1 diabetes immunotherapy using polyclonal regulatory T cells

Published:2015-11-25 Issue:315 Volume:7 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Bluestone Jeffrey A.¹,Buckner Jane H.²,Fitch Mark³,Gitelman Stephen E.⁴,Gupta Shipra²,Hellerstein Marc K.³,Herold Kevan C.⁵,Lares Angela¹,Lee Michael R.¹,Li Kelvin⁶,Liu Weihong¹,Long S. Alice²,Masiello Lisa M.¹,Nguyen Vinh⁷,Putnam Amy L.¹,Rieck Mary¹,Sayre Peter H.⁸,Tang Qizhi⁷

Affiliation:

1. Diabetes Center, University of California, San Francisco, San Francisco, CA 94143, USA.

2. Translational Research Program, Benaroya Research Institute at Virginia Mason, Seattle, WA 98101, USA.

3. Department of Nutritional Sciences and Toxicology, University of California, Berkeley, Berkeley, CA 94720, USA.

4. Department of Pediatrics, University of California, San Francisco, San Francisco, CA 94143, USA.

5. Departments of Immunobiology and Internal Medicine, Yale University School of Medicine, New Haven, CT 06520, USA.

6. KineMed Inc., Emeryville, CA 94608, USA.

7. Department of Surgery, University of California, San Francisco, San Francisco, CA 94143, USA.

8. Division of Hematology-Oncology, Department of Medicine, University of California, San Francisco, San Francisco, CA 94143, USA.

Abstract

Autologous regulatory T cells can be expanded and are well tolerated in patients with recent-onset type 1 diabetes.

Funder

Juvenile Diabetes Research Foundation International

BD Biosciences

Brehm Coalition

The Immune Tolerance Network

Caladrius Biosciences

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference43 articles.

1. Genetics, pathogenesis and clinical interventions in type 1 diabetes

2. Glycaemic control of Type 1 diabetes in clinical practice early in the 21st century: an international comparison

3. Current State of Type 1 Diabetes Treatment in the U.S.: Updated Data From the T1D Exchange Clinic Registry

4. Teplizumab (Anti-CD3 mAb) Treatment Preserves C-Peptide Responses in Patients With New-Onset Type 1 Diabetes in a Randomized Controlled Trial

5. Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial

Cited by 809 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic potentials of adoptive cell therapy in immune-mediated neuropathy;Journal of Autoimmunity;2024-12

2. Regulatory T cell-based therapy in type 1 diabetes: Latest breakthroughs and evidence;International Immunopharmacology;2024-10

3. Regulatory T cells: masterminds of immune equilibrium and future therapeutic innovations;Frontiers in Immunology;2024-09-03

4. Biological function of type 1 regulatory cells and their role in type 1 diabetes;Heliyon;2024-09

5. IL-27/Blimp-1 axis regulates the differentiation and function of Tim-3⁺ Tregs during early pregnancy;JCI INSIGHT;2024